Home > Result Summaries: Compounds > GSK573719 Result Summaries: GSK573719 GSKStudy ID Phase Title Summary (Download) 115321 phase 2 A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s)) 115408 phase 3 A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease (0 citation(s))
